American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.

dc.creatorBafica, Andre Luiz Barbosa
dc.creatorOliveira, Fabiano
dc.creatorFreitas, Luiz Antonio Rodrigues de
dc.creatorNascimento, Eliane Góes
dc.creatorBarral, Aldina Maria Prado
dc.date2014-07-09T14:09:10Z
dc.date2014-07-09T14:09:10Z
dc.date2003
dc.date.accessioned2023-09-26T22:42:10Z
dc.date.available2023-09-26T22:42:10Z
dc.identifierBÁFICA, A. L. B. et al. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. International Journal of Dermatology, v. 42, n. 3, p. 203-207, 2003.
dc.identifier0011-9059
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/7885
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8882137
dc.descriptionBackground American cutaneous leishmaniasis is characterized by single or multiple ulcerations. Cytokines, among other factors, have been shown to influence lesion development and tumoral necrosis factor-alpha is a major cytokine implicated in pathogenesis of ulcers. Observations We tested oral pentoxifylline, a known tumoral necrosis factor-alpha inhibitor, at doses of 400 mg (2–3x/day), associated to N-methylglucamine antimoniate (15 mg/kg/day) in two patients with American cutaneous leishmaniasis unresponsive to antimonial drugs. We observed a satisfactory response with quick cure of skin lesions of these patients. Conclusions Our results suggest that oral pentoxifylline in association to N-methylglucamine antimoniate should be consider in refractory cutaneous leishmaniasis patients
dc.formatapplication/pdf
dc.languageeng
dc.publisherThe International Society of Dermatology
dc.rightsopen access
dc.subjectAntiprotozoários/administração & dosagem
dc.subjectLeishmaniose Cutânea/quimioterapia
dc.subjectMeglumina/administração & dosagem
dc.subjectCompostos Organometálicos/administração & dosagem
dc.subjectPentoxifilina/administração & dosagem
dc.subjectQuimioterapia Combinada
dc.subjectFeminino
dc.subjectHumanos
dc.subjectLeishmaniose Cutânea/metabolismo
dc.subjectLeishmaniose Cutânea/patologia
dc.subjectMasculino
dc.subjectMeia-Idade
dc.subjectFator de Necrose Tumoral alfa/antagonistas & inibidores
dc.subjectFator de Necrose Tumoral alfa/metabolismo
dc.titleAmerican cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.
dc.typeArticle


Este ítem pertenece a la siguiente institución